Q&A: The new COVID vaccine booster is coming. Should you get it? The COVID-19 vaccine is getting an upgrade. Tribune News Service · Aug 28, 2022
What Are Whales Doing With Moderna Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Benzinga · Aug 26, 2022
Moderna Sues Pfizer/BioNTech for Patent Infringement over COVID Vaccine Moderna sued Pfizer and its German partner BioNTech on Friday for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic. Pfizer shares fell nearly 1%, while BioNTech US-listed shares were down about 1.5%… Asharq Al-Awsat · Aug 26, 2022
US Covid vaccine maker Moderna suing rivals Pfizer and BioNTech over jab The company said it believes its rivals’ vaccine infringes on patents Moderna filed between 2010 and 2016 Wales Online · Aug 26, 2022
Pfizer asks EU drug regulator to OK tweaked COVID vaccine Pharmaceuticals Pfizer and BioNTech say they have asked the European Medicines Agency to authorize their updated coronavirus booster vaccine that includes the most recent omicron subvariants The Independent UK · Aug 26, 2022
Moderna sues Pfizer over COVID-19 vaccine patents The vaccine maker alleges that its rivals Pfizer and BioNTech used some patented features of its mRNA technology to develop their COVID vaccines. WEKU · Aug 26, 2022
Moderna sues Pfizer and BioNTech over Covid-19 vaccine The vaccine maker said it had filed patent infringement lawsuits in the US and Germany. The Independent UK · Aug 26, 2022
Moderna sues Pfizer/BioNTech alleging patent infringement over Covid vaccine Moderna seeks unspecified damages in lawsuit over rivals’ jab Evening Standard · Aug 26, 2022
Covid infections at lowest level in two months- ONS High levels of coronavirus antibodies among the population means the rate of serious illness remains low Evening Standard · Aug 26, 2022
Moderna sues Pfizer, BioNTech over COVID vaccine technology Moderna Inc. sued Pfizer Inc. and BioNTech SE, claiming the technology in their COVID-19 shot infringes on its patents, a move that sets the stage for a massive legal clash between the vaccine titans. Tribune News Service · Aug 26, 2022
Moderna sues Pfizer over Covid vaccine Moderna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first Covid-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic. Bangkok Post · Aug 26, 2022
Moderna sues Pfizer over patents behind COVID-19 vaccine COVID-19 vaccine maker Moderna is suing its main competitors Pfizer and the German drugmaker BioNTech, accusing the rivals of copying Moderna’s technology in order to make their own vaccine The Independent UK · Aug 26, 2022
Moderna sues Pfizer-BioNTech accusing them of copying Covid shot technology ‘We believe that Pfizer and BioNTech unlawfully copied Moderna’s inventions, and they have continued to use them without permission,’ Moderna legal officer says The Independent UK · Aug 26, 2022
Moderna sues Pfizer, BioNTech over COVID-19 vaccine The lawsuit seeks unspecified monetary damages for patent infringement. Axios · Aug 26, 2022
The Independent UK · Aug 25, 2022 Tweaked COVID boosters close but how much will they help? COVID-19 vaccines tweaked to better match today’s omicron threat are expected to roll out in a few weeks but how much will they help
Benzinga · Aug 23, 2022 Moderna Whale Trades For August 23 A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 53 strange trades.
Tribune News Service · Aug 22, 2022 Pfizer files application for booster against latest variants Pfizer Inc. and BioNTech SE asked the U.S. to authorize a new COVID-19 booster shot customized against the currently circulating COVID-19 variants as governments race to protect their populations against the ever-mutating virus.
Wales Online · Aug 18, 2022 Everything you need to know about the new Covid vaccine that targets omicron variant o serious safety concerns have been identified for this new bivalent treatment
Daily Mirror · Aug 16, 2022 All over-50s to get a new Covid jab targeted to protect against Omicron variant Britain became the first country to approve a “bivalent” jab on Monday that directly targets Omicron and the original Covid-19 strain - as 29 million people will initially be invited for the vaccine
The Independent UK · Aug 16, 2022 ‘No second-rate vaccines’ health chief insists as half will miss out on dual-strain booster Roughly 29 million people are eligible for an autumn booster but there are just 13 million doses of the new bivalent Moderna jab available
Daily Record · Aug 16, 2022 Who can get Covid booster as new Omicron jab that targets Omicron to be used The new jab is bivalent, meaning it protects against the original Covid strain as well as the Omicron variant
WEKU · Aug 16, 2022 The U.K. approved omicron-specific booster shots. They're coming to the U.S. soon In the U.S., officials have asked vaccine makers to target BA.5, rather than the original omicron strain. That has delayed the boosters' development — but officials hope they will be more effective.
Wales Online · Aug 16, 2022 Full details of next Covid booster rollout -and Omicron jab will be used The Government has confirmed who will get another Covid injection and says new vaccine will be used
Pedestrian.tv · Aug 16, 2022 The UK Approved A Combo Vaccine To Protect Against Omicron Variants Pls Givvus That One Next Moderna's bivalent vaccine is seen as the "next step" in COVID protection.
Benzinga · Aug 15, 2022 Recap Of Monday's Biotech Catalysts - End Of the Day Summary Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…